成人一级黄色片,一出一进一爽一粗一大视频

Great News: Vigonvita Honored with CLS’s 2025 “Most Investable Company Award”發(fā)布時間：

manager — Mon, 29 Dec 2025 05:41:42 +0000

On December 29, 2025, the 8th Investment Annual Conference, guided by the Shanghai United Media Group and hosted by CLS, was grandly held in Hefei, Anhui. The site unveiled the “2025 Most Influential and Valuable Companies in the Capital Market” list. As an authoritative selection renowned for its significant brand influence and professional credibility within […]

The post Great News: Vigonvita Honored with CLS’s 2025 “Most Investable Company Award”發(fā)布時間： appeared first on Vigonvita Life Sciences Co., Ltd..

Vigonvita and Simcere Sign Exclusive Licensing and Collaboration Agreement for New Indications of VV116

manager — Wed, 03 Dec 2025 07:36:14 +0000

On December 3, 2025, ?Vigonvita Life Science Co., Ltd. (2630.HK,?hereinafter referred to as “Vigonvita”) entered into a licensing and collaboration agreement with Simcere Pharmaceutical Group (2096.HK,?hereinafter referred to as “Simcere”). Under this agreement, Vigonvita will grant Simcere the exclusive rights to develop, manufacture, and commercialize VV116 for respiratory syncytial virus (RSV) infection and human metapneumovirus […]

The post Vigonvita and Simcere Sign Exclusive Licensing and Collaboration Agreement for New Indications of VV116 appeared first on Vigonvita Life Sciences Co., Ltd..

Congratulations! Vigonvita (2630.HK) Officially Lists on the Main Board of the Hong Kong Stock Exchange Today

manager — Thu, 06 Nov 2025 07:11:02 +0000

On November 6, 2025, Vigonvita Life Sciences Co., Ltd., (hereinafter referred to as “Vigonvita”) was officially listed on the Main Board of the Hong Kong Stock Exchange (hereinafter referred to as “HKEX”) under the stock code?2630.HK.?This marks the beginning of a new journey for Vigonvita in the field of medicine and health. At the listing […]

The post Congratulations! Vigonvita (2630.HK) Officially Lists on the Main Board of the Hong Kong Stock Exchange Today appeared first on Vigonvita Life Sciences Co., Ltd..

First offline prescription issued! ED patients now have access to a highly active, highly selective PDE5 inhibitor.

manager — Mon, 08 Sep 2025 06:40:14 +0000

On September 4, 2025, the first offline prescription for simenafil hydrochloride tablets—a highly active, highly selective phosphodiesterase type 5 (PDE5) inhibitor featuring a novel chemical structure—was issued at the First Affiliated Hospital of Hunan University of Chinese Medicine. Prescribed for the treatment of erectile dysfunction (ED), this milestone marked the dawn of a new era […]

The post First offline prescription issued! ED patients now have access to a highly active, highly selective PDE5 inhibitor. appeared first on Vigonvita Life Sciences Co., Ltd..

VIGONVITA’s Class 1 new drug for erectile dysfunction, 昂偉達? Simenafil Hydrochloride Tablets, start first batch shipment.

manager — Wed, 06 Aug 2025 06:34:17 +0000

On 5th August 2025, Vigonvita Life Sciences Co., Ltd. (hereinafter referred to as ‘VIGONVITA’) held the official ceremony for the first batch shipment of Class 1 new drug, 昂偉達? Simenafil Hydrochloride Tablets, across the country. Company leaders and heads of relevant departments, along with leaders from the contract manufacturing organisation, witnessed this historic moment for […]

The post VIGONVITA’s Class 1 new drug for erectile dysfunction, 昂偉達? Simenafil Hydrochloride Tablets, start first batch shipment. appeared first on Vigonvita Life Sciences Co., Ltd..

VIGONVITA’s Class 1 New Drug 昂偉達? (Simenafil Hydrochloride Tablets) gets marketing approval for Erectile Dysfunction

manager — Thu, 10 Jul 2025 02:41:25 +0000

July 8, 2025?– 昂偉達? (Product Name: Simenafil Hydrochloride Tablets; R&D Code: TPN171), a Class 1 new drug collaboratively developed by Vigonvita Life Sciences Co., Ltd.,? Shanghai Institute of Materia Medica Chinese Academy of Sciences, Xinjiang Technical Institute of Physics and Chemistry? Chinese Academy of Sciences, and other institutions, has received marketing approval from the National […]

The post VIGONVITA’s Class 1 New Drug 昂偉達? (Simenafil Hydrochloride Tablets) gets marketing approval for Erectile Dysfunction appeared first on Vigonvita Life Sciences Co., Ltd..

Vigonvita Recognized as National-Level Specialized, Sophisticated, Distinctive and Innovative “Little Giant” Enterprise

manager — Fri, 15 Nov 2024 06:34:58 +0000

In September 2024, the Provincial Department of Industry and Information Technology announced the sixth batch of enterprises that passed the review by the Ministry of Industry and Information Technology (MIIT) and were recognized as national-level specialized, sophisticated, distinctive, and innovative “Little Giant” enterprises. Among them, Vigonvita Life Sciences Co., Ltd. was awarded this honor. The […]

The post Vigonvita Recognized as National-Level Specialized, Sophisticated, Distinctive and Innovative “Little Giant” Enterprise appeared first on Vigonvita Life Sciences Co., Ltd..

Class I New Drug VV261 Tablets Co-developed by Vigonvita et al. Approved for Clinical Trials

manager — Fri, 15 Nov 2024 06:26:50 +0000

On August 27, 2024, Vigonvita Shanghai Co., Ltd., Shanghai Institute of Materia Medica Chinese Academy of Sciences, the Wuhan Institute of Virology Chinese Academy of Sciences, and Vigonvita Life Sciences Co., Ltd. (“Vigonvita”) received the?Drug Clinical Trial Approval Notice?approved and issued by the National Medical Products Administration (NMPA), permitting the initiation of clinical trials […]

The post Class I New Drug VV261 Tablets Co-developed by Vigonvita et al. Approved for Clinical Trials appeared first on Vigonvita Life Sciences Co., Ltd..

The Phase II/III Clinical Trial of Deuremidevir Hydrobromide (VV116) Dry Suspension for the Treatment of Respiratory Syncytial Virus Infection in Infants and Children Officially Launched

june — Fri, 15 Nov 2024 06:26:13 +0000

From January 29 to 30, 2024, a “randomized, double-blind, placebo-controlled Phase II/III clinical trial evaluating the safety and efficacy of Deuremidevir Hydrobromide dry suspension in hospitalized infants and children with Respiratory Syncytial Virus infection” was successfully initiated at Shulan (Hangzhou) Hospital, Linfen Central Hospital, and Mianyang Central Hospital. This signifies that Deuremidevir Hydrobromide (V116) dry […]

The post The Phase II/III Clinical Trial of Deuremidevir Hydrobromide (VV116) Dry Suspension for the Treatment of Respiratory Syncytial Virus Infection in Infants and Children Officially Launched appeared first on Vigonvita Life Sciences Co., Ltd..

ONVITA? (TPN171), an Innovative Drug for the Treatment of Erectile Dysfunction (ED), Debuts at the 24th World Meeting on Sexual Medicine

june — Fri, 15 Nov 2024 06:23:34 +0000

From December 15 to 17, 2023, the ‘24th World Meeting on Sexual Medicine’ hosted by the International Society for Sexual Medicine (ISSM) was held in Dubai, UAE. This conference brought together more than 500 sexual medicine experts and scholars from over 100 countries and regions around the world to discuss the latest research achievements and […]

The post ONVITA? (TPN171), an Innovative Drug for the Treatment of Erectile Dysfunction (ED), Debuts at the 24th World Meeting on Sexual Medicine appeared first on Vigonvita Life Sciences Co., Ltd..